Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be...
CARA is here on a 15 minute chart. The earnings report is due March 4th. The price action is
already demonstrative of bullish momentum. CARA rose 60% this past week. It is still on sale
at 95% off its all time high. Spiking buying volume, and so an upgoing Price Vulme Trend and
squeeze release triggers on lower time frames all have CARA moving well prior to...
Cara Therapeutics (NASDAQ: NASDAQ:CARA ) is undergoing a significant transformation as it announces strategic shifts in its operations, including substantial layoffs and a departure at the executive level. The biopharmaceutical company is redirecting its focus towards its late-stage notalgia paresthetica program, necessitating a withdrawal from advanced chronic...
CARA: Cara Therapeutics, Inc.
2022-06-30 07:00:00
Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Nostalgia Paresthetica
On the 4hr and 8 hr there are low signals puddling up all over the place. This is ready to pop. In the Past the lowest pop witht hese same signals was 61% move. Taking this to at the lowest $16.85
by iCantw84it
03.26/22
$CARA - The stock has had a support level of $11.9 since '17. It only went lower in March '20. Now it has also fallen a bit lower, but it is trying to get back up. If you buy at the current level, stop below $10.8, with $15.5 and $17.8 as growth targets.
Its not an investment recommendation
CARA: Cara Therapeutics, Inc.
2022-01-10 08:00:00
Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients
this could go anyway at the moment but strong volume and huge gap to fill on this chart but we have earnings coming out Monday after hours so could pump if beats or could act as a good price entry for long swing. Im holding calls for the move over 18.15 I want 20+.
target gap fill or high of prior session
scanner showed me CARA as top market gainer, and a 5 min breakdown entry was good for a 2-3$ move to the downside (15%)
$CARA Target 17.68 for 24.42%
Or double position at 10.74
I'm not sure if I published this one when I first bought on that hellacious dip, haha. 🤣 Anyway, it looks like it found a little bit of support here so, might as well publish it here
This might not be a trade you want to play... I will post better ones... just for reference here.
—
On the far right of...
Cara fib analysis trend reversal back to last support level. Level 2 quotes showing sell side order flow. Looks like bearish trend for tomorrows earnings call.
Cara joining the SmallCap 600 is normally a pretty bullish signal as it means more of the larger brokers and market makers will start to keep an eye on it, as well as various funds and etfs might look to buy as well. Worth keeping an eye on it.
I was in this some years ago go out in Feb before this covid hit. I was up 100%. i didn't pay attention. Left it make $5 bucks. That is okay, I didn't lose a penny and I learned a lot. Now CARA, i see you again, this time ready.
Waiting for the gap fill to climb to $22, if it breaches the high, it may get to the $26, if it clears $26, I'll see you at ATH.
named...
As you can see we are sitting in the mid range of the support and resistance . You can clearly see a pattern in movement between spikes.
We have 3 levels to enter here.
We can either jump on the red line which is a pretty aggressive entry, or we can find a entry on the support level / red level, which is more safe but there is also a chance to miss the entry....
